Latest Novartis Pharmaceuticals Canada Inc. Stories
-- In Quebec alone 386,000 people suffer from COPD and it is the fourth leading cause of death in Canada.
-- Fourth indication for injection treatment that can stabilize and improve vision(1) -- mCNV a leading cause of visual impairment among those 20-50 years of age(9) Since
-- Today is the first ever International Urticaria Day, an international event to increase urticaria awareness and improve care around the globe and let people living with urticaria
-- LANTERN study met primary endpoint demonstrating non-inferiority of Ultibro® Breezhaler® 110/50 mcg vs Advair* Diskus* (SFC) 50/500 mcg followed by statistically
-- LCZ696 mortality benefit exceeded what was achieved with enalapril, an ACE-inhibitor, when replacing enalapril combined with current treatment
DORVAL QC, Feb.
-- Ultibro(TM) Breezhaler®1(QVA149), a long-term once-daily dual bronchodilator, received Health Canada approval on December 23rd 2013 for the treatment of
- an ornament or knob in the shape of a flower